Arrhythmias & electrophysiologyRandomised controlled trial
Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk
- Randomised controlled trial
- multicentre
- open-label
- adjudicator-masked
- superiority
Authors' conclusion
Among patients with atrial fibrillation at intermediate risk for stroke, DOAC therapy led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes at 24 months than no anticoagulation.
Study context
- Population
- Patients with AF at intermediate stroke risk (CHA2DS2-VASc 1 in men, 2 in women), South Korea
- Participants
- 1,803 patients
- Comparison
- Direct oral anticoagulant (DOAC) vs no anticoagulation
- DOACn = 902
- No anticoagulantn = 901reference
- Primary endpoint
- Composite of:
- Stroke
- Systemic embolism
- Major bleeding
- CV death
- Follow-up
- 24 months
Primary result
As reported in the abstract
Each group vs no anticoagulantDifference, percentage points (95% CI)P value
DOAC
−1.0(−2.0 to −0.1)
P = 0.03Each group vs no anticoagulantHazard ratio (95% CI)
DOAC
0.31(0.10–0.94)
Further findings
Stroke · 24 months · cumulative incidence
events
| Outcome | DOAC | No anticoagulant |
|---|---|---|
| CV death | 0 | 0 |
Systemic embolism
- Incidence appeared similar in the two groups
Safety
Serious adverse events
Major bleeding
- Incidence appeared similar in the two groups
Original publication
Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk. N Engl J Med. Published 28 August 2026. doi:10.1056/nejmoa2607978
Summarised from the published abstract; every number is checked against it